{
    "organizations": [],
    "uuid": "3a0013cfcb93aff53225ae63af62174c36f54a94",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-abiomed-receives-approval-for-expa/brief-abiomed-receives-approval-for-expanded-fda-indication-for-cardiomyopathy-with-cardiogenic-shock-idUSASB0C5EK",
    "ord_in_thread": 0,
    "title": "Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Abiomed Inc:\n* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK\n* ABIOMED INC - APPROVAL EXPANDS PREVIOUS FDA INDICATION FOR ACUTE MYOCARDIAL INFARCTION CARDIOGENIC SHOCK AND PCCS, RECEIVED IN APRIL 2016 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T21:24:00.000+02:00",
    "crawled": "2018-02-14T12:26:16.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "abiomed",
        "inc",
        "abiomed",
        "receives",
        "approval",
        "expanded",
        "fda",
        "indication",
        "cardiomyopathy",
        "cardiogenic",
        "shock",
        "abiomed",
        "inc",
        "approval",
        "expands",
        "previous",
        "fda",
        "indication",
        "acute",
        "myocardial",
        "infarction",
        "cardiogenic",
        "shock",
        "pccs",
        "received",
        "april",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}